Goldline Pharmaceutical IPO GMP Today, Price & Details
Goldline Pharmaceutical IPO GMP Today, Price Band, Subscription Status, Allotment & Listing Details
About Goldline Pharmaceutical
Goldline Pharmaceutical is making its debut on the stock market through the SME platform of the BSE, aiming to raise capital for its growth initiatives. Operating within the pharmaceutical sector, the company is involved in the manufacturing and marketing of a range of pharmaceutical formulations. The firm's current scale of operations, as indicated by its recent financial performance, suggests a focused business model with a clear product portfolio.
The company has reported a revenue of ₹21.41 Cr and a Profit After Tax (PAT) of ₹2.22 Cr for the period under review. This translates into an Earnings Per Share (EPS) of ₹4.1. The IPO is structured as a complete fresh issue, with the entire issue size of ₹11.61 Cr comprising new equity shares. This means that all the funds raised will directly flow into the company's coffers, intended to fuel its expansion and operational enhancements.
In terms of its competitive positioning, Goldline Pharmaceutical aims to leverage its existing market presence and product offerings. The fresh capital infusion is earmarked for specific purposes, which could include enhancing manufacturing capabilities, expanding its distribution network, or investing in research and development to broaden its product pipeline. The company's strategy will be key to its ability to capture market share and deliver sustained growth in the dynamic pharmaceutical landscape.
Goldline Pharmaceutical IPO — Investment Analysis
Goldline Pharmaceutical's IPO is priced at a band of ₹41 per share, with a face value of ₹10. At this price, the company is seeking to raise ₹11.61 Cr through a pure fresh issue. The Earnings Per Share (EPS) stands at ₹4.1, and with the issue priced at ₹41, this results in a Price-to-Earnings (P/E) multiple of approximately 10.01x. This valuation appears relatively attractive when compared to industry averages, especially for an SME player. The single price point in the band suggests a fixed offering, simplifying the subscription process. The lot size is fixed at 3000 shares, requiring a minimum investment of ₹123,000.
Financially, Goldline Pharmaceutical presents a mixed but promising picture. The company has demonstrated a revenue of ₹21.41 Cr and a PAT of ₹2.22 Cr, indicating healthy profitability. Its EBITDA margin stands at an impressive 20.78%, which is a strong indicator of operational efficiency. Furthermore, return ratios are robust, with a Return on Net Worth (RONW) of 27.37% and a Return on Capital Employed (ROCE) of 38.45%. These figures suggest that the company effectively utilizes its capital to generate profits and that its net worth is growing at a good pace.
The growth outlook for Goldline Pharmaceutical is tied to its ability to effectively deploy the IPO proceeds. The fresh issue capital is intended to bolster its operational capacity and market reach. However, key risks include the inherent volatility of the SME segment, where smaller companies can experience significant price swings. Sector-specific risks, such as regulatory changes or increased competition, also warrant consideration. The absence of an Offer for Sale (OFS) means the company is not diluting existing promoter holdings, which can be seen as a positive by some investors, but it also means that all proceeds are going into the company itself, with no immediate liquidity for existing shareholders.
Subscription levels in SME IPOs are often a strong indicator of market sentiment. High subscription across all categories, particularly from High Net-worth Individuals (HNIs) and retail investors, suggests strong demand and potentially good listing gains. Conversely, muted subscriptions might signal caution. For Goldline Pharmaceutical, tracking the subscription data closely will be crucial in gauging investor appetite. The overall sentiment for pharmaceutical SMEs can also influence demand. Investors should consult a SEBI-registered financial advisor before making investment decisions.
Disclaimer: This analysis is auto-generated from publicly available financial data and should not be considered investment advice. Always consult a SEBI-registered financial advisor before making investment decisions.
Goldline Pharmaceutical IPO — Pros & Cons
Strengths
- The company boasts strong profitability metrics, with an impressive EBITDA margin of 20.78%. This indicates efficient cost management and a healthy operational model, which is a positive sign for investor confidence.
- Goldline Pharmaceutical demonstrates excellent capital efficiency, evidenced by a RONW of 27.37% and ROCE of 38.45%. These high return ratios suggest that the company is effectively leveraging its assets and equity to generate profits.
- The P/E ratio of 10.01x appears attractive, especially for a company operating in the growth-oriented pharmaceutical sector. This valuation could offer a good entry point for investors seeking potential capital appreciation.
- The IPO is structured as a 100% fresh issue, meaning all funds raised will directly benefit the company for its expansion plans. This focus on internal growth can be beneficial for long-term value creation.
- The company's net worth stands at ₹12.38 per share, and the IPO price of ₹41 suggests a reasonable premium over its book value, indicating investor confidence in its future prospects.
Risks
- The IPO is being launched on the BSE SME platform, which is known for higher volatility and lower liquidity compared to the main board exchanges. This could lead to significant price fluctuations post-listing.
- The lot size of 3000 shares requires a minimum investment of ₹123,000, which might be a significant outlay for retail investors with smaller portfolios. This could limit participation from a segment of the retail investor base.
- While profitability is good, the total issue size of ₹11.61 Cr is relatively small. This could mean limited institutional interest and potentially a narrower market for the shares after listing.
- The company's financial history, while showing positive returns, is not provided in extensive detail. A deeper understanding of its revenue trajectory and cost structures over multiple years would offer a more comprehensive view.
- The pharmaceutical sector is highly regulated and competitive. Goldline Pharmaceutical will need to navigate these challenges effectively to maintain its growth and profitability in the long run.
Goldline Pharmaceutical IPO Details
| Company Name | Goldline Pharmaceutical |
|---|---|
| IPO Type | SME |
| Exchange | BSE |
| Price Band | ₹41 - ₹43 |
| Face Value | ₹10 per share |
| Lot Size | 3000 shares |
| Min Investment | ₹129,000 |
| Total Issue Size | ₹11.61 Cr |
|---|---|
| Fresh Issue | ₹11.61 Cr |
| Registrar | Bigshare Services Pvt.Ltd. |
| Lead Manager | List of Issues managed, Cumulative Capital Pvt.Ltd. |
| IPO Status | Listed |
Goldline Pharmaceutical IPO Dates
Goldline Pharmaceutical IPO Subscription Status
Day-wise Subscription Trend
| Date | Retail | NII/HNI | QIB | Total |
|---|---|---|---|---|
| 14 May 2026 | 881.15x | 1,662.39x | 180.22x | 840.81x |
| 13 May 2026 | 139.51x | 146.48x | 1.31x | 100.21x |
| 12 May 2026 | 34.07x | 24.46x | 1.31x | 22.35x |
Goldline Pharmaceutical IPO Listing Performance
Goldline Pharmaceutical IPO listed on BSE on 19 May 2026 at ₹60, a premium of 39% over the issue price of ₹43. Investors who received allotment made a profit of ₹50,250 per lot (3000 shares) on listing day.
Goldline Pharmaceutical IPO — Key Highlights
- The company exhibits a strong ROCE of 38.45%, indicating excellent efficiency in deploying capital.
- With an EBITDA margin of 20.78%, Goldline Pharmaceutical demonstrates robust operational profitability.
- The IPO is priced at a P/E of 10.01x, which appears reasonable for the sector.
- The entire issue size of ₹11.61 Cr is a fresh issue, directly funding the company's growth.
- Return on Net Worth (RONW) stands at a healthy 27.37%.
- The Net Asset Value (NAV) per share is ₹12.38.
Goldline Pharmaceutical Financial Performance
| Metric (₹ Cr) | FY 2023 | FY 2024 | FY 2025 | 9M FY 2026 |
|---|---|---|---|---|
| Revenue | 19.85 | 23.57 | 28.06 | 21.41 |
| Expenses | 19.45 | 21.04 | 24.20 | 18.40 |
| Net Income (PAT) | 0.26 | 1.80 | 2.83 | 2.22 |
Goldline Pharmaceutical IPO Valuations & Key Metrics
Valuation Ratios
| EPS | ₹4.10 |
|---|---|
| P/E Ratio | 10.01x |
| NAV | ₹12.38 |
| Debt/Equity | 1.500 |
Return Metrics
| RONW (%) | 27.37% |
|---|---|
| ROCE (%) | 38.45% |
| EBITDA Margin | 20.78% |
| Employees | 112 |
Goldline Pharmaceutical IPO Reservation / Allocation
Goldline Pharmaceutical IPO Lead Manager & Registrar
Book Running Lead Manager
List of Issues managed, Cumulative Capital Pvt.Ltd.
IPO Registrar
Bigshare Services Pvt.Ltd.
Goldline Pharmaceutical IPO — Frequently Asked Questions
What is Goldline Pharmaceutical IPO GMP today?
As of today, the Grey Market Premium (GMP) for Goldline Pharmaceutical IPO is ₹17 per share, indicating a potential listing premium of 39.5% above the issue price of ₹43.
What is the price band and lot size of Goldline Pharmaceutical IPO?
Goldline Pharmaceutical IPO has a price band of ₹41 to ₹43 per equity share with a face value of ₹10. The minimum lot size is 3000 shares, requiring a minimum investment of ₹129,000 at the upper band.
What are the important dates for Goldline Pharmaceutical IPO?
Goldline Pharmaceutical IPO opens for subscription on 12 May 2026 and closes on 14 May 2026. Allotment is expected on 15 May 2026. The shares are expected to list on BSE on 19 May 2026.
What is the investor category allocation in Goldline Pharmaceutical IPO?
The shares are reserved as follows — Qualified Institutional Buyers (QIB): 49.65%, Non-Institutional Investors (NII/HNI): 15.22%, and Retail Individual Investors: 35.13%.
How can I apply for Goldline Pharmaceutical IPO?
You can apply for Goldline Pharmaceutical IPO through your bank's net banking ASBA facility or via UPI-based application through any stockbroker platform. Ensure you have sufficient funds in your bank account as the amount will be blocked until allotment. The registrar for this IPO is Bigshare Services Pvt.Ltd..
What is the subscription status of Goldline Pharmaceutical IPO?
Goldline Pharmaceutical IPO has been subscribed 840.81 times overall. Retail category: 881.15x, NII/HNI: 1,662.39x, QIB: 180.22x.
What is Goldline Pharmaceutical IPO price band and lot size?
The Goldline Pharmaceutical IPO comes with a price band of ₹41 to ₹41 per share. The lot size is fixed at 3000 shares, meaning you'll need to apply for at least this many shares. This translates to a minimum investment of ₹123,000 (3000 shares x ₹41).
The face value of each share is ₹10.
Is Goldline Pharmaceutical IPO worth investing in?
Goldline Pharmaceutical presents a compelling case with strong return ratios like RONW of 27.37% and ROCE of 38.45%, coupled with healthy margins. The P/E of 10.01x also appears attractive.
However, it's crucial to consider the risks associated with the SME platform, including higher volatility. Investors should carefully weigh these factors against the company's financial performance and growth prospects. Investors should consult a SEBI-registered financial advisor before making investment decisions.
What is Goldline Pharmaceutical IPO GMP today?
Grey Market Premium (GMP) is an unofficial indicator of demand for an IPO. While it can provide some insight into market sentiment, it's not a guaranteed predictor of listing performance. For Goldline Pharmaceutical, any available GMP figures should be viewed with caution.
Remember, GMP is not regulated and can fluctuate significantly, so it shouldn't be the sole basis for your investment decisions.
How to apply for Goldline Pharmaceutical IPO?
You can apply for the Goldline Pharmaceutical IPO through the ASBA (Application Supported by Blocked Amount) facility offered by your bank or through the UPI (Unified Payments Interface) mechanism. Ensure you have a demat account and a bank account linked. Your funds will remain blocked until the allotment process is complete.